Lowenstein represented Tonix Pharmaceuticals Holding Corp. in the transaction.Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a clinical-stage biopharmaceutical company, announced its $25 million acquisition of two currently-marketed…
Lowenstein represented Tonix Pharmaceuticals Holding Corp. in the transaction.Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a clinical-stage biopharmaceutical company, announced its $25 million acquisition of two currently-marketed…
You must be a Standard 1 Year member to access this content.
…
You must be a Standard 1 Year member to access this content.